Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 21;9(2):39.
doi: 10.3390/antibiotics9020039.

Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review

Musaiwale M Kamfose  1 , Francis G Muriithi  2 , Thomas Knight  3 , Daniel Lasserson  3 , Gail Hayward  4
Affiliations
Review

Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review

Musaiwale M Kamfose et al. Antibiotics (Basel). .

Abstract

Background: Methicillin-susceptible Staphylococcus aureus (MSSA) is a common pathogen associated with a range of clinically important infections. MSSA can cause deep-seated infections requiring prolonged courses of intravenous antibiotic therapy to achieve effective resolution. The move toward ambulatory or outpatient delivery of parenteral antibiotics has led to an increase in the use of ceftriaxone as a pragmatic first choice given its advantageous single daily dosing schedule.

Objective: To compare the efficacy of once daily ceftriaxone in the treatment of infections due to confirmed or suspected MSSA to multiple dosing regimes of anti-staphylococcal antibiotics.

Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Global Health, PubMed, EMBASE and CINAHL for randomised controlled trials as well as prospective and retrospective cohort studies that compared ceftriaxone to any multiple dosing regime of anti-staphylococcal antibiotics. Outcome measures were the proportion of patients with a resolution of infection based on time after initiation of therapy, adverse reactions, recurrence and duration of hospital admission.

Results: We included two randomized controlled trials, one prospective observational study and three retrospective cohort studies (643 participants; 246 children, 397 adults). There was no difference in time to resolution of symptoms. The number of adverse reactions, recurrence of bacteraemia and duration of hospital stay were not significantly different between ceftriaxone and other anti-staphylococcal antibiotics.

Conclusions: Based on a small number of low-quality studies, ceftriaxone is as effective as multiple dosing regimes for the treatment of infections due MSSA. An appropriately powered randomized trial is required to demonstrate equivalence and cost effectiveness.

Keywords: anti-staphlococcal antibiotics; intravenous ceftriaxone; mssa; multiple dosing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
Risk of bias in the randomised controlled trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McDanel J.S., Perencevich E.N., Diekema D.J., Herwaldt L.A., Smith T.C., Chrischilles E.A., Dawson J.D., Jiang L., Goto M., Schweizer M.L. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin. Infect. Dis. 2015;61:361–367. doi: 10.1093/cid/civ308. - DOI - PubMed
    1. Seaton R.A., Bell E., Gourlay Y., Semple L. Nurse-led management of uncomplicated cellulitis in the community: Evaluation of a protocol incorporating intravenous ceftriaxone. J. Antimicrob. Chemother. 2005;55:764–767. doi: 10.1093/jac/dki092. - DOI - PubMed
    1. Caplan G.A., Sulaiman N.S., Mangin D.A., Aimonino Ricauda N., Wilson A.D., Barclay L. A meta-analysis of “hospital in the home”. Med. J. Aust. 2012;197:512–519. doi: 10.5694/mja12.10480. - DOI - PubMed
    1. Phe K., Dao D., Palmer H.R., Tama V.H. In vitro ceftriaxone susceptibility in methicillin-susceptible staphylococcus aureus. Antimicrob. Agents Chemother. 2015;59:1370. doi: 10.1128/AAC.04531-14. - DOI - PMC - PubMed
    1. Coenen S., Muller A., Adriaenssens N., Vankerckhoven V., Hendrickx E., Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient parenteral antibiotic treatment in Europe. J. Antimicrob. Chemother. 2009;64:200–205. doi: 10.1093/jac/dkp135. - DOI - PubMed

LinkOut - more resources